tetano
Editor, Senior Moderator
Minerva Anestesiol
. 2022 Mar 22.
doi: 10.23736/S0375-9393.22.16054-2. Online ahead of print.
Platelet activation state in early stages of Covid-19
Filippo Consolo[SUP] 1 2 [/SUP], Patrizia Della Valle[SUP] 3 [/SUP], Marco Saracino[SUP] 4 [/SUP], Marta Bonora[SUP] 5 [/SUP], Giovanni Donadoni[SUP] 6 [/SUP], Fabio Ciceri[SUP] 5 7 [/SUP], Moreno Tresoldi[SUP] 8 [/SUP], Armando D'Angelo[SUP] 3 [/SUP], Giovanni Landoni[SUP] 5 4 [/SUP], Alberto Zangrillo[SUP] 5 4 [/SUP]
Affiliations
Abstract
Background: Platelet activation at the early stage of COVID-19 is poorly described. The need for antiplatelet therapy in patients with COVID-19 remains controversial. We characterized the platelet activation profile in hospitalized patients at the early stage of COVID-19 using the modified prothrombinase Platelet Activation State (PAS) assay.
Methods: Sixteen patients admitted to the emergency department of the IRCCS San Raffaele Scientific Institute (Milano, Italy) between February 8 and April 2021 were enrolled. All patients presented with respiratory symptoms and tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Platelet activation was measured via the PAS assay within 24 hours from patients' hospital admission. Data were compared with those measured in n=24 healthy subjects (controls).
Results: Platelet activation was significantly higher in COVID-19 patients with respect to controls (PAS = 0.63 [0.58-0.98]% vs. 0.46 [0.40-0.65]%, respectively; p=0.03). Of note, highest PAS values were measured in the two patients with the worst clinical outcome, i.e., death because of respiratory failure (PAS = 2.09% and 1.20%, respectively). No differences in standard coagulation parameters were noted between these two patients and those who were later discharged home.
Conclusions: This study provides evidences of significant platelet activation state at the early stage of COVID-19 and suggests that the patient-specific platelet activation profile is a reliable clinical marker to stratify COVID-19 patients at high risk of poor clinical outcome who might potentially benefit from antiplatelet therapy.
. 2022 Mar 22.
doi: 10.23736/S0375-9393.22.16054-2. Online ahead of print.
Platelet activation state in early stages of Covid-19
Filippo Consolo[SUP] 1 2 [/SUP], Patrizia Della Valle[SUP] 3 [/SUP], Marco Saracino[SUP] 4 [/SUP], Marta Bonora[SUP] 5 [/SUP], Giovanni Donadoni[SUP] 6 [/SUP], Fabio Ciceri[SUP] 5 7 [/SUP], Moreno Tresoldi[SUP] 8 [/SUP], Armando D'Angelo[SUP] 3 [/SUP], Giovanni Landoni[SUP] 5 4 [/SUP], Alberto Zangrillo[SUP] 5 4 [/SUP]
Affiliations
- PMID: 35315619
- DOI: 10.23736/S0375-9393.22.16054-2
Abstract
Background: Platelet activation at the early stage of COVID-19 is poorly described. The need for antiplatelet therapy in patients with COVID-19 remains controversial. We characterized the platelet activation profile in hospitalized patients at the early stage of COVID-19 using the modified prothrombinase Platelet Activation State (PAS) assay.
Methods: Sixteen patients admitted to the emergency department of the IRCCS San Raffaele Scientific Institute (Milano, Italy) between February 8 and April 2021 were enrolled. All patients presented with respiratory symptoms and tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Platelet activation was measured via the PAS assay within 24 hours from patients' hospital admission. Data were compared with those measured in n=24 healthy subjects (controls).
Results: Platelet activation was significantly higher in COVID-19 patients with respect to controls (PAS = 0.63 [0.58-0.98]% vs. 0.46 [0.40-0.65]%, respectively; p=0.03). Of note, highest PAS values were measured in the two patients with the worst clinical outcome, i.e., death because of respiratory failure (PAS = 2.09% and 1.20%, respectively). No differences in standard coagulation parameters were noted between these two patients and those who were later discharged home.
Conclusions: This study provides evidences of significant platelet activation state at the early stage of COVID-19 and suggests that the patient-specific platelet activation profile is a reliable clinical marker to stratify COVID-19 patients at high risk of poor clinical outcome who might potentially benefit from antiplatelet therapy.